The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies
- 26 April 2025
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115470
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer PatientsClinical Colorectal Cancer, 2021
- Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer, 2020
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialThe Lancet Oncology, 2020
- The characterization, management, and future considerations for ErbB-family TKI-associated diarrheaBreast Cancer Research and Treatment, 2019
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyThe Lancet Oncology, 2015
- A review of relative dose intensity and survival in patients with metastatic solid tumorsCritical Reviews in Oncology/Hematology, 2015
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerNew England Journal of Medicine, 2014
- The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancerCancer Chemotherapy and Pharmacology, 2014